Odyssey Health Business Summary

Odyssey Health, Inc. (ODYY) is a medical technology company transitioning from a development-stage entity to a revenue-generating enterprise through a dual-track business model. The company generates revenue via strategic sub-licensing agreements, such as its exclusive worldwide rights to the BreastCheck® non-invasive breast abnormality test, and a recently secured multi-million-dollar, nine-year maintenance service contract for a commercial medical property intended to provide stable, recurring cash flow. Its primary business segments include medical device development—headlined by the CardioMap heart monitoring system and the Save-A-Life choking rescue device—and medical property services. Within the competitive landscape, Odyssey Health operates as a niche innovator, positioning itself against larger incumbents like iRhythm Technologies in cardiac monitoring, and Medtronic and Stryker in the broader medical instrument and emergency care markets by focusing on portable, low-cost, and non-invasive diagnostic solutions. The leadership team is led by J. Michael Redmond, who serves as Chairman, President, and CEO, bringing over 35 years of medical device experience from roles at Abbott Laboratories and Bioject Inc. He is supported by CFO and Secretary Christine M. Farrell, whose background includes nearly two decades of financial leadership at Bioject Medical Technologies, and COO Greg Gironda, a pharmaceutical veteran with experience at Genentech and King Pharmaceuticals. The company’s board and advisory committees feature high-pedigree professionals, including Jerome H. Casey, a former senior executive at Genzyme Corporation, and Ricky W. Richardson, previously a Corporate Director at Danaher. Notable institutional support and financing have been provided by entities such as Lincoln Park Capital, LLC, Mast Hill Fund, L.P., and LGH Investments, LLC, which have been instrumental in restructuring the company's debt and funding its commercialization pivot.